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Abstract
Treatment of non-small cell lung cancer (NSCLC) has been transformed by targeted therapies 
directed against molecular aberrations specifically activated within an individual patient’s tumor. 
However, such therapies are currently only available against a small number of such aberrations, 
and new targets and therapeutics are needed. Our laboratory has previously identified the MERTK 
receptor tyrosine kinase (RTK) as a potential drug target in multiple cancer types, including 
NSCLC. We have recently developed UNC2025 – the first-in-class small molecule inhibitor 
targeting MERTK with pharmacokinetic properties sufficient for clinical translation. Here we 
utilize this compound to further validate the important emerging biologic functions of MERTK in 
lung cancer pathogenesis, to establish that MERTK can be effectively targeted by a clinically 
translatable agent, and to demonstrate that inhibition of MERTK is a valid treatment strategy in a 
wide variety of non-small cell lung cancer cell lines independent of their driver oncogene status, 
including in lines with an EGFR mutation, a KRAS/NRAS mutation, an RTK fusion, or another or 
unknown driver oncogene. Biochemically, we report the selectivity of UNC2025 for MERTK, and 
its inhibition of oncogenic downstream signaling. Functionally, we demonstrate that UNC2025 
induces apoptosis of MERTK-dependent NSCLC cell lines, while decreasing colony formation in 
vitro and tumor xenograft growth in vivo in murine models. These findings provide further 
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evidence for the importance of MERTK in NSCLC, and demonstrate that MERTK inhibition by 
UNC2025 is a feasible, clinically relevant treatment strategy in a wide variety of NSCLC sub-
types, which warrants further investigation in clinical trials.
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Introduction
Personalized medicine – therapy against the activated molecular targets within an individual 
patient’s tumor – has transformed the field of clinical oncology. However, few personalized 
therapeutics are currently available, and the majority of cancer patients still receive 
conventional cytotoxic regimens. In NSCLC, for example, targeted therapies against 
activated EGFR or ALK improve survival compared to conventional chemotherapy, but 
only approximately 10% of newly diagnosed patients have a tumor with an activating EGFR 
mutation, while just 5% have an ALK translocation (1–5). For the remaining 85% of 
patients, opportunities clearly exist to identify new therapeutic targets and compounds.
Our laboratory and others have investigated the role of the TAM family, consisting of the 
RTK’s TYRO3, AXL, and MERTK, in NSCLC. AXL has been well established as a 
promising target in primary and therapy-resistant NSCLC (6,7). AXL expression is detected 
in 48% – 93% of patient samples, correlates with an invasive phenotype in cell lines, and 
with lymph node status and clinical stage in patients (8,9). Additionally, AXL has been 
shown to mediate resistance to conventional cytotoxic chemotherapeutics, as well as to 
EGFR-targeted agents (8, 10, 11). MERTK is also over-expressed or ectopically expressed 
in a multitude of human cancers, and activates a diverse network of downstream pro-
oncogenic signaling pathways (8, 12–20). In NSCLC, MERTK is over-expressed in 
approximately two-thirds of patient tumor samples, regardless of histology (8). Additionally, 
activation of MERTK in NSCLC cell lines induces pro-oncogenic signaling, and genetic 
inhibition of MERTK using shRNA decreases this signaling, resulting in increased 
apoptosis, increased chemosensitivity, decreased colony formation in vitro, and inhibition of 
tumor formation in a murine subcutaneous xenograft model (8). Finally, a monoclonal 
antibody against MERTK decreases colony formation and increases chemosensitivity to 
carboplatin, further validating the multiple functional roles of MERTK in NSCLC (21).
As our laboratory and others have validated MERTK as a promising target in NSCLC and 
other cancers, we have taken the next step of developing therapies against MERTK, 
including a monoclonal antibody (21, 22), and small molecule TKIs (17, 23–27). We have 
previously published on the synthesis and structure-activity relationships of several first-
generation tool compound TKIs, and here report the pre-clinical characterization of 
UNC2025, the first with sufficient pharmacokinetic properties for murine-based studies and 
potential clinical translation (28). UNC2025 is approximately 15-fold selective for MERTK 
over AXL, and MERTK is the most potently inhibited kinase, with the exception of FLT3. 
UNC2025 is approximately equipotent against FLT3 and MERTK. While known to play 
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important roles in subsets of acute myeloid leukemia, where it is constitutively activated 
through mutation, FLT3 has not been shown to be expressed in NSCLC, and therefore 
effects of UNC2025 in NSCLC are likely to be MERTK-dependent (29). In addition, 
UNC2025 is approximately 20-fold selective for MERTK over TYRO3, and has more than 
700-fold selectivity for MERTK over MET, another closely related RTK to the TAM family 
with established roles in NSCLC. In this study, we demonstrate selectivity of UNC2025 for 
MERTK within the TAM family in NSCLC cells, UNC2025-mediated abrogation of 
MERTK-mediated pro-oncogenic downstream signaling, and functional consequences, 
including induction of cellular apoptosis and decreased colony formation in vitro, and 
inhibition of tumor growth in vivo. Additionally, we demonstrate that UNC2025 is broadly 
efficacious in a wide variety of cell lines, independent of driver oncogene status. 
Specifically, UNC2025 retained potent efficacy against cell lines containing an EGFR 
mutation, a KRAS/NRAS mutation, an RTK fusion, or another or unknown driver oncogene. 
These results support further consideration of testing UNC2025 in clinical trials.
Materials and Methods
Cell culture and treatment
All cell lines were maintained in RPMI medium supplemented with 10% fetal bovine serum 
(FBS), penicillin (100 U/mL), and streptomycin (100 μg/ml) until plating for experiments. 
Specific culture conditions for each experiment are provided within the relevant sub-sections 
below. All cell line identities were confirmed by the authors by comparison of short tandem 
repeat profiles to publically available databases. Testing was performed at the time of 
acquisition of each cell line, as well as approximately annually thereafter. Validated STR 
profiles were not available for some of the cell lines (H157, H3122, HCC4011, SF188) but 
the profiles obtained did not match any other cell line. The A172, A549, G361, H226, 
H1299, H2009, HMCB, and U251 cell lines were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA), the Colo699 cell line was purchased from the 
German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany), 
the SF188 cell line was obtained from the UCSF Brain Tumor Bank, and the Calu3, H157, 
H322, H358, H441, H460, H1650, H1975, H2126, H2228, H3122, H3255, HCC827, 
HCC4006, HCC4011, and LC-2/ad cell lines were obtained from Drs. John Minna and Adi 
Gazdar (University of Texas Southwestern Medical Center, Dallax, TX). UNC2025 and 
UNC1653 were synthesized as previously described (25, 27).
Western blotting
Cells were either lifted with 0.02% EDTA in PBS and re-suspended in lysis buffer (50 mM 
HEPES pH 7.5, 150 mM NaCl, 10 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM 
Na3VO4) supplemented with protease inhibitors (Complete Mini, Roche Molecular 
Biochemicals) or washed with PBS and scraped into lysis buffer. Total protein 
concentrations were determined and western blotting was performed as previously described 
(8).
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Antibodies for western blotting
For western blotting, the following antibodies were obtained from Cell Signaling: pAKT 
(S473, Cat# 9271), AKT (Cat# 9272), pERK1/2 (T202/Y204, Cat# 9106), ERK1/2 (Cat# 
9102), c-KIT(Cat# 3074), Survivin (Cat# 2808), α-tubulin (Cat# 2125), and TYRO3 (Cat# 
5585). Additional antibodies used for western blotting include AXL (R&D Systems, 
AF154), FLT3 (Santa Cruz, sc-480), pMERTK (Y749, Y753, Y754, PhosphoSolutions), 
MERTK (Abcam ab52968), pan-TRK (Santa Cruz, sc-11), and pTyrosine (4G10 Platinum, 
Millipore 05-1050). Horseradish peroxidase (HRP)-conjugated secondary antibodies (goat 
anti-rabbit, Bio-Rad 170-6515; goat anti-mouse, Bio-Rad 170-6516; donkey anti-goat, Santa 
Cruz sc-2020) were used for detection of proteins using enhanced chemiluminescence.
Immunoprecipitation and detection of phosphorylated MERTK, AXL, and TYRO3
After one hour of treatment with DMSO, UNC2025, or UNC1653 in RPMI medium 
supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/ml), cells 
were treated with pervanadate phosphatase inhibitor (0.12 mM Na3VO4 in 0.002% H2O2 in 
PBS) for 5 minutes (A549, H1299, H2228) or 1 minute (Colo699), and then lysed. Lysates 
were incubated with antibodies against MERTK (R&D Systems, MAB8912), AXL (R&D 
Systems, AF154), or TYRO3 (Cell Signaling, 5585) and with rec-Protein G-sepharose 4B 
beads (Invitrogen 10-1242) overnight. Beads were then washed twice with lysis buffer, 
resuspended in Laemmli buffer (62.5 mM Tris-HCl pH 6.8, 25% glycerol, 5% beta-
mercaptoethanol, 2% SDS, and 0.01% bromophenol blue), boiled, and resolved on 
polyacrylamide gels. Blots were probed for phospho-MERTK or phospho-tyrosine, stripped, 
and re-probed for total MERTK (Abcam, 52968), AXL (R&D Systems, AF154), or TYRO3 
(Cell Signaling, 5585).
Assessment of downstream signaling
Recombinant human Gas6 (rhGas6, 885-GS) was purchased from R&D Systems. Sub-
confluent cultures were starved in serum-free medium for two hours and then cultured in the 
presence of UNC2025 or vehicle control for an additional two hours prior to Gas6 
stimulation for 10 minutes. Lysates were quantified by Bradford assay and analyzed by 
western blot. Alternatively, cultures were treated with UNC2025 or vehicle control for 72 
hours in RPMI medium supplemented with 10% FBS, penicillin (100 U/mL), and 
streptomycin (100 μg/ml), prior to lysis, quantification, and analysis on western blot 
(Supplemental Figure 2).
Assessment of apoptosis and cell death
A549, Colo699, H1299, and H2228 cells were treated with UNC2025, UNC1653, or DMSO 
vehicle control for 72 hours in RPMI medium supplemented with 10% FBS, penicillin (100 
U/mL), and streptomycin (100 μg/ml). Supernatants were collected and combined with cells 
after lifting with EDTA. Cells were then stained with 0.2 μM YO-PRO®-1-iodide (YO-
PRO-1) and 1.5 μM propidium iodide (PI) (Invitrogen). Uptake of dyes was assessed by 
flow cytometry using an FC500 cytometer and CXP analysis software (Beckman Coulter).
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Soft agar colony formation assay
15,000 cells per well were plated in 0.35% Noble agar in RPMI, and overlaid on 0.5% 
Noble agar in RPMI in 6-well plates. Agar layers were overlaid with 2 mL RPMI medium 
supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/ml) 
containing DMSO vehicle control, UNC2025, or UNC1653. This medium layer was 
aspirated and replaced three times per week. After two weeks of growth, medium was 
aspirated, and cells were stained with 200 uL nitrotetrazoline blue chloride (NTB) (Biosynth 
N-8100) overnight. Colonies were then counted using a GelCount colony counter and 
software (Oxford Optronix).
Subcutaneous xenograft model
All experiments involving animals were approved by the University of Colorado 
Institutional Animal Care and Use Committee. Two million H2228 cells or 5.5 million A549 
cells were suspended in 100 uL PBS (with 50% Matrigel for the A549 cell line) and injected 
subcutaneously into the flank of athymic Nude-Foxn1nu mice. Tumors were measured 
weekly with calipers, and volume was calculated using the formula Volume=πa2b/6, where 
‘a’ represents the shortest diameter measured perpendicular to the longest diameter, ‘b’. 
When tumors reached an average size of 100-200 mm3, mice were randomized to groups 
and treated twice daily by oral gavage with saline or UNC2025 at 30 mg/kg or 50 mg/kg, 
administered at a dose of 10 ml/kg.
Statistical analysis
Statistical analyses were performed using Prism 5 software (GraphPad Software, Inc.). An 
unpaired t-test was used for analysis of apoptosis and xenograft assays, a paired t-test was 
used for analysis of soft agar colony number after normalization to vehicle-treated controls 
wihin each replicate, and IC50 values were calculated using Segmental Linear Regression. 
All data are representative of at least three independent experiments.
Results
UNC2025 Selectively Inhibits MERTK Phosphorylation
To test the selectivity of UNC2025 within the TAM family, levels of phosphorylated 
MERTK, AXL, and TYRO3 were assessed in H2228, A549, Colo699, and H1299 cells after 
one hour of treatment with UNC2025 or UNC1653, a negative control compound that lacks 
activity against MERTK (27) (Figure 1A). UNC2025 potently inhibited MERTK 
phosphorylation at doses in the low nanomolar range, with IC50 values below 50 nM in all 
four cell lines studied (Figure 1B). In addition, UNC2025 was selective for MERTK over 
the related kinases AXL and TYRO3. Phospho-AXL was expressed in the H2228, A549, 
and H1299 cell lines, while Colo699 cells did not express AXL. Phospho-TYRO3 was 
expressed in the H2228, H1299, and A549 cell lines, but was not reliably detected in the 
Colo699 cell line. Regardless of expression levels, treatment with UNC2025 at doses up to 
300 nM was far less potent against phospho-AXL or phospho-TYRO3 than against 
phospho-MERTK in any of these cell lines. Importantly, AXL and TYRO3 were two of the 
most potently inhibited kinases after MERTK in enzymatic assays characterizing the 
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specificity of UNC2025 against a panel of over 300 kinases (28). Other kinases determined 
to have greater sensitivity to UNC2025 than AXL and TYRO by this in vitro screening 
assay include FLT3, c-KIT, and TRKA, however, none of these proteins were expressed in 
any of the four cell lines studied (Supplemental Figure 1). All other of the 300+ kinases 
assayed in the selectivity profiling are predicted to be less sensitive to UNC2025 than even 
TYRO3, and thus MERTK appears to be the only relevant target inhibited by UNC2025 in 
these cell lines and at these concentrations. While it is impossible to rule out the contribution 
of partial inhibition of other kinases to the effects observed with UNC2025, our extensive 
characterization of the translation of in vitro potency to cellular phospho-protein potency 
demonstrates that kinases less inhibited by UNC2025 than TYRO3 in vitro would also be 
expected to be less inhibited in cells, and therefore less than 50% inhibited at doses up to 
300 nM (25). Finally, UNC1653 did not decrease phosphorylation of MERTK at doses up to 
300 nM (Figure 1C). Interestingly, total MERTK expression was increased in response to 
treatment with higher doses of UNC2025 in 3 of the 4 lines tested.
Oncogenic Signaling Downstream of MERTK is Blocked by UNC2025
MERTK is known to stimulate a large network of downstream signaling proteins, most 
commonly through the MAPK and PI3K/AKT pathways (20). To determine whether 
treatment with UNC2025 abrogated these effects, cells were treated with UNC2025 or 
vehicle control prior to stimulation with the TAM-family ligand GAS6 (Figure 2A). 
Decreased levels of pAKT and/or pERK1/2 were detected after UNC2025 treatment in all 
four cell lines studied; however, effects were cell line specific. In the H2228 cell line, 
UNC2025 reduced basal levels of both pAKT and pERK1/2 (lane 1 vs. lane 3). Similarly, 
basal pAKT levels were reduced in the A549 cell line (lane 1 vs. lane 3), while pERK1/2 
levels were unaffected. In the Colo699 cell line, pAKT levels were unaffected, however, 
Gas6-induced pERK1/2 stimulation was inhibited by UNC2025 (lane 2 vs. lane 4). Basal 
pERK1/2 levels were undetectable in this cell line. Finally, in the H1299 cell line, both basal 
(lane 1 vs. lane 3) and stimulated (lane 2 vs. lane 4) pAKT and pERK1/2 were decreased by 
UNC2025 administration.
Unexpectedly, and in contrast to the Colo699 and H1299 cell lines, GAS6 induced a 
decrease of pAKT and pERK1/2 in the H2228 and A549 cell lines at the one hour time-point 
measured. Compensatory regulatory mechanisms are hypothesized to play a role in this 
effect, as has been shown to be the case in other oncogenic signaling pathways, however 
specific negative regulatory pathways here remain unidentified (30). In spite of these 
paradoxical effects of GAS6, positive effects of UNC2025 were demonstrated in all four cell 
lines assayed. However; long-term signaling assays were next utilized in order to identify a 
more conserved downstream marker of UNC2025 response. Cultures were treated with 300 
nM UNC2025 for 72 hours, lysed, and analyzed by western blot. Survivin, a member of the 
inhibitor of apoptosis protein (IAP) family, was consistently decreased after UNC2025 
treatment (Figure 2B). As Survivin has been shown to be a promising drug target, we sought 
to determine whether Survivin levels were decreased in response to UNC2025 treatment in 
additional solid tumor cell lines representing a variety of tumor types (31). We treated four 
additional NSCLC cell lines, three glioblastoma cell lines, and two melanoma cell lines with 
UNC2025, and examined Survivin levels in whole cell lysates. In 10 of the 13 solid tumor 
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cell lines assessed, Survivin levels were dramatically decreased. Survivin protein expression 
was decreased in six of the eight total NSCLC cell lines assessed, all three glioblastoma cell 
lines, and one of the two melanoma cell lines (Supplemental Figure 2).
pAKT, pERK1/2, and Survivin are all well-validated targets in the mechanism of action of 
NSCLC pathogenesis, and indeed all three have therapeutics in various stages of clinical 
trials for lung cancer patients (32, 33). The inhibition of these targets by UNC2025 
suggested mechanisms of action by which functional effects would be expected to occur, 
and that such functional testing was warranted.
MERTK Inhibition by UNC2025 Induces Apoptotic Cell Death
We next hypothesized that the potent effects mediated by UNC2025 on MERTK 
phosphorylation and downstream oncogenic signaling would translate to a functional 
decrease in survival of NSCLC cells. To test this hypothesis, NSCLC cells were treated with 
300 nM UNC2025 or UNC1653 for 72 hours, stained with YO-PRO-1 and PI dyes, and 
analyzed by flow cytometry to assess apoptotic cell death. Treatment with UNC2025, but 
not UNC1653, significantly increased the fraction of apoptotic and dead cells in all four cell 
lines studied (Figure 3). UNC2025 increased cell death from basal levels of 23.9±4.2%, 
13.8±2.2%, 9.9±1.6%, and 44.2±0.1%, in the H2228, A549, Colo699, and H1299 cell lines, 
to 40.5±3.8%, 50.3±7.1%, 32.9±6.2%, and 59.1±3.4%, respectively (p = 0.0428, p=0.0081, 
p=0.0224, p=0.0118). Levels of apoptosis were not significantly different from basal levels 
after UNC1653 treatment in any of the four NSCLC cell lines.
UNC2025 Decreases Colony-Formation in a Dose-Dependent Manner
A soft agar assay was utilized to determine the long-term functional effects of UNC2025 
treatment on NSCLC colony formation. UNC2025, UNC1653, or vehicle control was 
administered three times per week. After two weeks of growth, colonies were stained and 
counted (Figure 4A). Treatment with UNC2025, but not UNC1653, significantly reduced 
colony formation of all four NSCLC cell lines assayed (Figure 4B). At a dose of 300nM 
UNC2025, colony formation was reduced by 99.2%, 98.1%, 98.2%, and 80.1%, in the 
H2228, A549, Colo699, and H1299 cell lines, respectively (p<0.0001 for each).
Since UNC2025 robustly decreased colony formation in all four of the studied NSCLC cell 
lines, we sought to determine if this trend was conserved in a larger panel of NSCLC cell 
lines with different driver oncogene statuses. Cell lines harboring an EGFR mutation, an 
RTK fusion, a KRAS or NRAS mutation, and those with another or with no known driver 
were assessed in the soft agar assay. IC50 values were calculated for each cell line (Figure 
4C). Driver oncogene status did not correlate with sensitivity to UNC2025, as IC50’s 
between 50nM and 350 nM were observed in cell lines of each type studied. Similarly, 
expression of MERTK or phospho-MERTK also did not correlate with sensitivity to 
UNC2025. As seen in Supplemental Figure 3, cell lines were arranged from most to least 
sensitive, utilizing the IC50 values from Figure 4C, and assayed for pMERTK levels by 
immunoprecipitation, or total MERTK levels by western blot of whole cell lysates. 
Although all cell lines express pMERTK/MERTK, levels of both variably increase and 
decrease from the most sensitive to least sensitive cell lines, indicating a lack of predictive 
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value for response. This is potentially due to the activation of alternative signaling pathways 
present in these cell lines, however, these remain unidentified at this time.
UNC2025 Inhibits Tumor Growth in Murine Models
As UNC2025 shows potent anti-tumor effects in vitro, and since it has the pharmacokinetic 
properties for in vivo administration, we determined the effects of UNC2025 in vivo in 
murine subcutaneous xenograft models. Mice were injected with H2228 (Figure 5A) or 
A549 (Figure 5B) NSCLC cells and tumors were established until an average size of 
approximately 100 cubic millimeters (A549) or 150 cubic millimeters (H2228) was reached. 
Mice were then treated twice daily by oral gavage with either saline vehicle or 50 mg/kg 
UNC2025 and tumor size was measured weekly. Tumor growth was significantly impaired 
in mice treated with UNC2025, as indicated by significantly smaller tumor volumes relative 
to mice treated with saline at every measurement point in the H2228 cell line (p=0.0193, 
p=0.0058, p=0.0011, and p=0.0034 after one, two, three, and four weeks of treatment, 
respectively). In the A549 cell line, tumor volume between the two groups were 
significantly different during the final two weeks of measurements (p=0.0021 and p=0.0015, 
respectively). At the end of the study period in the H2228 study, tumor volume was reduced 
by 70.2%, from 1183±258 mm3 in saline-treated mice, to 352±51 mm3 in mice that had 
received UNC2025. In the A549 cell line study, final tumor volume was reduced by 61.9%, 
from 373±57 mm3 in saline-treated mice, to 143±28 mm3 in UNC2025-treated mice. 
Additionally, in a dose-reduction study, mice were again injected with A549 tumor cells, 
and allowed to establish until an average size of approximately 200 mm3 was reached 
(Figure 5C). As before, mice were then randomized and treated with saline, 50 mg/kg 
UNC2025, or a lower-dose treatment arm of 30 mg/kg UNC2025. Mice were again treated 
twice daily orally, and tumors measured weekly. Tumor growth was nearly completely 
inhibited in both treatment arms of this study, and there was no significant difference 
between the doses of UNC2025. To further analyze the mechanism behind this effect, a 
pharmacokinetic study assaying concentrations of UNC2025 in the plasma and tumors of 
mice post-treatment was utilized. Mice harboring established A549 tumors were treated 
twice daily for three days with saline or UNC2025 at 30 mg/kg or 50 mg/kg, in order to 
establish a steady-state level. Plasma and tumors were harvested one or 12 hours after the 
final treatment, to capture peak and trough concentrations of UNC2025. Specimens were 
analyzed by LC-MS/MS for compound concentration (Supplemental Table 1). Importantly, 
trough concentrations of 161 nM and 50 nM were found in plasma of mice treated with 50 
mg/kg and 30 mg/kg UNC2025, respectively, well within the 50 – 300 nM range utilized 
within the functional assays in this manuscript. In light of this, it is somewhat unsurprising 
that these doses are equally efficacious in Figure 5C, as both maintain trough levels above 
50 nM; however, 30 mg/kg may be nearing the minimum effective dose, as doses lower than 
50 nM are relatively ineffective in in vitro assays previously shown.
Discussion
MERTK was initially cloned from a B-lymphoblastoid expression library and its role in a 
wide variety of blood cancers has subsequently been extensively characterized (7, 34). More 
recently, it has become increasingly appreciated that MERTK plays important roles in solid 
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tumors as well. In NSCLC in particular, MERTK is aberrantly expressed in approximately 
two-thirds of patient tumors, and its activation results in increased downstream pro-
oncogenic signaling. Genetic inhibition of MERTK by shRNA in NSCLC cells inhibits this 
signaling network, resulting in induction of apoptosis, decreased colony formation in vitro, 
enhanced chemosensitivity, and decreased tumor formation in vivo in a murine model (8). 
MERTK was further validated as an important target in NSCLC by the finding that Mer590, 
a monoclonal antibody targeting MERTK, decreases pro-oncogenic signaling, increases 
apoptosis, increases chemosensitivity, and decreases colony formation in NSCLC cell lines 
(21). Importantly, two of the cell lines used in the current study, A549 and Colo699, were 
used extensively in the shRNA target validation and Mer590 monoclonal antibody studies, 
respectively. The consistency between the effects observed in these studies using three 
different mechanisms of MERTK inhibition provides strong support that the observed 
phenotypes are indeed MERTK-dependent.
MERTK has been extensively validated as a potential therapeutic target not only in NSCLC, 
but also in a multitude of other cancers. For this reason, our group recently began pursuing 
the synthesis of novel small molecule tyrosine kinase inhibitors targeting MERTK. We have 
generated a series of novel compounds representing the first-in-class MERTK-targeted small 
molecule inhibitors (17, 23–28). UNC2025 is the first compound of these inhibitors with 
pharmacokinetic properties suitable for in vivo study and potential clinical translation. Here, 
we have investigated the utility of UNC2025 in NSCLC and have demonstrated that 
UNC2025 is selective for MERTK over related TAM-family members AXL and TYRO3, 
inhibits downstream signaling through AKT, ERK1/2 and Survivin, induces apoptotic cell 
death, decreases colony formation in vitro, and decreases tumor formation in vivo in murine 
xenograft models. Importantly, sensitivity to UNC2025 did not depend on driver oncogene 
status. Development of MERTK-selective TKIs for clinical application may therefore 
provide a molecularly-targeted treatment option for patients without known oncogenic 
mutations or with a wide variety of alternative driver mutations.
One mechanism by which MERTK inhibition may mediate anti-tumor activity is inhibition 
of Survivin expression. We have previously demonstrated decreased total levels of Survivin 
in response to shRNA-mediated MERTK inhibition, and here confirm this finding with 
UNC2025-mediated MERTK inhibition (8). Survivin plays important roles in several critical 
aspects of oncogenesis, where it functions to promote tumor cell survival, proliferation, 
metastasis, and chemoresistance, and can also contribute to tumor angiogenesis (31). 
Additionally, Survivin is an extremely cancer-specific target, as it is expressed widely in a 
multitude of cancer types, but not in the vast majority of normal adult tissues. These 
qualities have made Survivin a top target for new therapy development, and several novel 
therapies are currently in clinical development. However, early results have not been as 
impressive as hoped, and additional strategies to target Survivin, including potentially via 
UNC2025-mediated MERTK inhibition, are needed. Additionally, as MERTK-targeted 
therapeutics transition to the clinic, pharmacodynamic biomarkers indicating response of the 
tumor to treatment will become a necessity. Survivin has previously been used as a tumor 
biomarker due to its tumor-specific expression. We have demonstrated decreased Survivin 
levels following treatment with UNC2025 in a wide variety of solid tumor cell lines, 
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including the majority of NSCLC lines assayed. Decreased Survivin expression is a more 
consistent indicator of UNC2025-mediated MERTK inhibition than changes in phospho-
AKT and phospho-ERK levels, and is more easily measured than phospho-MERTK. It is 
conceivable that Survivin levels could be determined pre- and post-UNC2025 administration 
as an early marker of tumor response to facilitate clinical decisions regarding therapeutic 
strategy.
In addition to MERTK, important roles for AXL have also been characterized in NSCLC (6, 
8). AXL expression has been correlated with lymph node status and clinical stage in patient 
tumor samples and can mediate resistance to EGFR-targeted therapy (9–11). Several TKIs 
against AXL are in various stages clinical development (7). The data presented here suggest 
that continued development of MERTK-selective TKIs may allow a second TAM-family 
member to be targeted clinically. Additionally, dual inhibition of both MERTK and AXL 
represents another potential therapeutic strategy and may be more efficacious than inhibition 
of either single TAM-family member.
UNC2025 is a novel TKI that is selective for MERTK within the TAM family, inhibits 
MERTK’s downstream signaling network, induces apoptotic cell death and inhibits colony 
formation in tumor cell cultures independent of driver oncogene status, and decreases tumor 
growth in vivo in murine models. These promising effects mediated by UNC2025 in pre-
clinical studies demonstrate that MERTK-targeted TKIs deserve further investigation and 
optimization toward clinical trials.
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Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Financial Support: D.K. Graham is supported by a grant from the NIH (RO1CA137078). K.D. Davies is supported 
by a grant from the NIH (SPORE in Lung Cancer - P50CA058187), and the Lung Cancer Colorado Fund. This 
research was funded in part by a research grant from Merck & Co., Inc.
The authors would like to thank Christopher Porter, Karen Helm, Christine Childs, Lester Acosta, Kristina Heide, 
and Erin Erdahl in the University of Colorado Cancer Center Flow Cytometry Core.
References
1. Maemondo M, Inoue A, Kabayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or 
chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362:2380–
8. [PubMed: 20573926] 
2. Shepherd FA, Rodrigues Pereira J, Cluleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in 
previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353:123–32. [PubMed: 
16014882] 
3. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib 
or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 
J Clin Oncol. 2013; 31:3327–34. [PubMed: 23816960] 
4. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy 
in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368:2385–94. [PubMed: 23724913] 
5. Minuti G, D’Incecco A, Cappuzzo F. Targeted therapy for NSCLC with driver mutations. Expert 
Opin Biol Ther. 2013; 13:1402–12.
Cummings et al. Page 10













6. Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine 
kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets. 2010; 14:1073–90. 
[PubMed: 20809868] 
7. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine-sensing 
receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014; 14:769–85. [PubMed: 
25568918] 
8. Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, et al. Mer or 
Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances 
chemosensitivity of human non-small cell lung cancer. Oncogene. 2013; 32:3420–31. [PubMed: 
22890323] 
9. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, et al. Expression of axl in lung 
adenocarcinoma and correlation with tumor progression. Neoplasia. 2005; 7:1058–64. [PubMed: 
16354588] 
10. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase 
causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012; 44:852–60. 
[PubMed: 22751098] 
11. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, et al. AXL mediates 
resistance to cetuximab therapy. Cancer Res. 2014; 74:5152–64. [PubMed: 25136066] 
12. Linger RM, Lee-Sherick AB, DeRyckere D, Cohen RA, Jacobsen KM, McGranahan A, et al. Mer 
receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood. 
2013; 122:1599–609. [PubMed: 23861246] 
13. Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, et al. Lymphoblastic 
leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene. 
2006; 25:6092–100. [PubMed: 16652142] 
14. Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, et al. Inhibition of 
MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute 
lymphoblastic leukemia. Blood Cancer J. 2013; 3:e101. [PubMed: 23353780] 
15. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, et al. Ectopic 
expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin 
Cancer Res. 2006; 12:2662–9. [PubMed: 16675557] 
16. Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, et al. 
Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid 
leukemia. Oncogene. 2013; 32:5359–68. [PubMed: 23474756] 
17. Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, et al. MERTK receptor 
tyrosine kinase is a therapeutic target in melanoma. J Clin Invest. 2013; 123:2257–67. [PubMed: 
23585477] 
18. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, et al. Inhibition of Mer and 
Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved 
chemosensitivity. Mol Cancer Ther. 2010; 9:1298–307. [PubMed: 20423999] 
19. Wu YM, Robinson DR, Hung HJ. Signal pathways in up-regulation of chemokines by tyrosine 
kinase MER/NYK in prostate cancer cells. Cancer Res. 2004; 64:7311–20. [PubMed: 15492251] 
20. Cummings CT, Deryckere D, Earp HS, Graham DK. Molecular pathways: MERTK signaling in 
cancer. Clin Cancer Res. 2013; 19:5275–80. [PubMed: 23833304] 
21. Cummings CT, Linger RMA, Cohen RA, Sather S, Kirkpatrick GD, Davies KD, et al. Mer590, a 
novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation 
and increases chemosensitivity in non-small cell lung cancer. Oncotarget. 2014; 5:10434–45. 
[PubMed: 25372020] 
22. Rogers AE, Le JP, Sather S, Pernu BM, Graham DK, Pierce AM, et al. Mer receptor tyrosine 
kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. 
Oncogene. 2012; 31:4171–81. [PubMed: 22179835] 
23. Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, et al. Discovery of Novel 
Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic 
Leukemia. ACS Med Chem Lett. 2012; 3:129–34. [PubMed: 22662287] 
Cummings et al. Page 11













24. Liu J, Zhang W, Stashko MA, Deryckere D, Cummings CT, Hunter D, et al. UNC1062, a new and 
potent Mer inhibitor. Eur J Med Chem. 2013; 65:83–93. [PubMed: 23693152] 
25. Zhang W, Zhang D, Stashko MA, Deryckere D, Hunter D, Kireev D, et al. Pseudo-Cyclization 
through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as 
New Mer Kinase Inhibitors. J Med Chem. 2013; 56:9683–92. [PubMed: 24195762] 
26. Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, et al. UNC569, a 
novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro 
and in vivo. Mol Cancer Ther. 2013; 12:2367–77. [PubMed: 23997116] 
27. Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, et al. Efficacy of a 
Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. 
Oncotarget. in press. 
28. Zhang W, DeRyckere D, Hunter D, Liu J, Stashko M, Minson KA, et al. UNC2025, a potent and 
orally bioavailable MER/FLT3 dual inhibitor. J Med Chem. 2014; 57:7031–41. [PubMed: 
25068800] 
29. Serve H, Flesch K, Serve S, Fenski R, Berdel WE. Expression and function of Flt3/flk2 in human 
tumor cell lines. Int J Oncol. 1999; 14:765–70. [PubMed: 10087327] 
30. Harris DL, Joyce NC. Protein tyrosine phosphatase, PTP1B, expression and activity in rat corneal 
endothelial cells. Mol Vis. 2007; 13:785–96. [PubMed: 17563729] 
31. Athanasoula, KCh; Gogas, H.; Polonifi, K.; Vaiopoulos, AG.; Polyzos, A.; Mantzourani, M. 
Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. 
Cancer Lett. 2014; 347:175–82. [PubMed: 24560928] 
32. Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J 
Carcinog. 2013; 12:22. [PubMed: 24574860] 
33. Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S, Cheung CH. Treat cancers by targeting survivin: 
just a dream or future reality? Cancer Treat Rev. 2013; 39:802–11. [PubMed: 23453862] 
34. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression 
analysis of a novel human protooncogene, c-mer. Cell Growth Differ. 1994; 5:647–57. [PubMed: 
8086340] 
Cummings et al. Page 12














UNC2025 Selectively Inhibits MERTK Activation. A) Structures of UNC2025 and 
UNC1653. B,C) H2228, A549, Colo699, and H1299 cells were treated with the indicated 
doses of UNC2025 (B) or negative control compound UNC1653 (C) for one hour prior to 
preparation of cell lysates. MERTK, AXL, or TYRO3 proteins were immunoprecipitated 
and phospho- and total proteins were detected by immunoblot.
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UNC2025 Inhibits Signaling Pathways Downstream of MERTK. A) Sub-confluent cell 
cultures were starved for two hours in serum-free medium, and then treated with UNC2025 
(300 nM) or an equivalent volume of DMSO vehicle for an additional two hours prior to 
stimulation with Gas6 (200 nM) for 10 minutes. Lysates were prepared and phospho- and 
total AKT and ERK1/2 were detected by immunoblot. B) Cells were treated with 300 nM 
UNC2025, UNC1653, or DMSO vehicle control for 72 hours in RPMI medium 
supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/ml). Lysates 
were prepared and Survivin was detected by immunoblot.
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UNC2025 Induces Apoptosis in NSCLC cells. H2228, A549, Colo699, and H1299 cells 
were treated with 300 nM UNC2025, UNC1653, or DMSO vehicle for 72 hours in RPMI 
medium supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/
ml), prior to staining with YO-PRO®-1 iodide (YO-PRO-1) and propidium iodide (PI) dyes 
and assessment of dye uptake by flow cytometry. Early apoptotic cells are stained 
selectively with YO-PRO-1, while late apoptotic and dead cells take up both dyes. A) 
Representative histograms for the H1299 cell line are shown. B) Mean values and standard 
errors derived from 3 independent experiments are shown (*P<0.05, **P<0.01).
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UNC2025 Inhibits Colony Formation in Soft Agar. The indicated cell lines were cultured in 
0.35% Noble Agar overlaying 0.5% Noble Agar in 6-well plates. Agar layers were overlaid 
with a medium layer containing UNC2025, UNC1653, or DMSO vehicle. The medium layer 
was aspirated and replaced three times a week for two weeks, after which time cells were 
stained with NTB and counted on a colony counter. A) Representative cultures of the H2228 
cell line are shown. B) Mean colony numbers and standard errors derived from at least 3 
independent experiments are shown (**P<0.01, ***P<0.001). C), IC50 values were 
calculated from soft agar data generated using a large panel of NSCLC cell lines with 
different genetic driver mutations. IC50 values (nM) are as follows: Driver Unknown or 
Other – Calu3: 90.7, Colo699: 69.6, H226: 57.3, H322: 190.4, H2126: 97.5. EGFR Mutant – 
H1650: 236.8, H1975: 70.0, H3255: 204.5, HCC827: 182.5, HCC4006: 88.8, HCC4011: 
62.7. KRAS/NRAS Mutant – A549: 60.5, H157: 256.8, H358: 78.9, H441: 233.2, H460: 
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96.0, H1299: 157.6, H2009: 339.8. RTK Fusion – H2228: 91.6, H3122: 238.6, LC-2/ad: 
37.4.
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UNC2025 Inhibits NSCLC tumor growth in vivo: H2228 (A) or A549 (B,C) cells were 
injected subcutaneously into the flanks of Nude mice and tumors were established until an 
approximate average volume of 150 mm3 (A), 100 mm3 (B), or 200 mm3 (C). Mice were 
then treated twice daily by oral gavage with 50 mg/kg UNC2025, 30 mg/kg UNC2025 (C 
only), or 10 ml/kg saline vehicle. Tumors were measured weekly until study completion. In 
(A), data from two independent experiments were combined, for a total of 11 saline-treated 
mice and 12 UNC2025-treated mice; in (B) there were 9 saline-treated mice and 10 
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UNC2025-treated mice; and in (C) there were 6 saline-treated mice and 7 mice in each of 
the UNC2025 treatment groups. (*P<0.05, **P<0.01)
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